{"product_id":"fujifilm-pestle-analysis","title":"Fujifilm Holdings PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSkip the Research. Get the Strategy.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how political shifts, economic cycles, and rapid technological advances are reshaping Fujifilm Holdings' competitive landscape—our concise PESTLE highlights risks and opportunities you need now. Ideal for investors and strategists, the full analysis delivers actionable intelligence and ready-to-use insights to inform decisions. Purchase the complete PESTLE for the detailed breakdown and gain a tactical edge.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical Trade Tensions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe US-China trade friction strains Fujifilm Holdings' supply chain for semiconductor materials and imaging components, with Japan's electronics exports to China falling 12% year-on-year in 2024, pressuring procurement costs and lead times. Export controls on high-tech equipment force Fujifilm to navigate complex licensing regimes after US-led controls expanded in 2023, affecting access to advanced lithography and inspection tools. Management must monitor diplomatic shifts as tariff threats and non-tariff barriers could erode the 2024 Electronics segment operating profit margin of 6.8%, introducing sudden cost and market-share risks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Policy Reforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpas fujifilm pivots to healthcare national policy shifts and reimbursement cuts directly affect margins japan medical fee revision trimmed some imaging reimbursements by up impacting device revenue. government investments planned hospital upgrade india pm-ayushman expansion demand for diagnostic supporting sales segment trillion fy2024 austerity in eu markets with spending growth slowing pressures pricing on pharmaceuticals devices squeezing profitability.\u003e\n\u003c\/pas\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegional Stability in Manufacturing Hubs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFujifilm operates over 60 manufacturing and R\u0026amp;D sites globally, with significant hubs in Thailand, Vietnam and the Netherlands, making it sensitive to regional stability; political unrest or 2024–25 labor-law reforms in Southeast Asia could disrupt output and raise unit costs by an estimated 3–6%, while supply-chain interruptions previously cost global manufacturers ~1.5% of annual revenue; geographic diversification remains essential to ensure continuity and limit localized volatility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Subsidies for Biotechnology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpmany governments committed over billion collectively to domestic biopharma capacity in creating subsidy and tax-incentive programs benefiting cdmos fujifilm segment reported revenue fy2024 positioning it capture subsidized projects contract wins.\u003e\n\u003cpstrategic alignment with national industrial policies and subsidy criteria is crucial for fujifilm to access grants secure priority regulatory reviews win supply-chain resilience contracts that governments prioritize.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGovernment commitments: \u0026gt;$50bn (2024–2025)\u003c\/li\u003e\n\u003cli\u003eFujifilm FY2024 biopharma revenue: ¥357.6bn\u003c\/li\u003e\n\u003cli\u003eBenefits: grant access, tax incentives, regulatory fast-tracking\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pstrategic\u003e\u003c\/pmany\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eData Sovereignty and Privacy Regulations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePolitical moves toward data localization force Fujifilm to rearchitect cloud-based medical imaging and document management, increasing IT CAPEX; global healthcare cloud spend reached $65.4B in 2024, pressuring compliance investments.\u003c\/p\u003e\n\u003cp\u003eNationalistic data policies dictate where Fujifilm stores and processes patient data, affecting revenue recognition across 30+ markets and operational footprints in Japan, US and EU.\u003c\/p\u003e\n\u003cp\u003eAdhering to varied international privacy standards is mandatory to avoid fines—GDPR penalties reached €2.3B in 2023—and to preserve trust among healthcare clients.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eData localization raises IT CAPEX and OPEX\u003c\/li\u003e\n\u003cli\u003eOperations impacted across 30+ jurisdictions\u003c\/li\u003e\n\u003cli\u003eRegulatory fines (eg €2.3B GDPR total 2023) risk reputation and revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeo-risks, policy cuts and data rules squeeze electronics \u0026amp; healthcare margins in 2024\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGeopolitical tensions (US-China export controls since 2023) and 2024 tariff risks increase procurement costs and compress the Electronics margin (6.8% in 2024); healthcare policy shifts (Japan 2024 fee cuts up to 1.5%) and slower US\/EU health spending growth (2.1% in 2024) pressure device pricing; government biopharma subsidies (\u0026gt; $50bn 2024–25) favor Fujifilm (biopharma revenue ¥357.6bn FY2024); data localization and compliance (global healthcare cloud spend $65.4bn 2024) raise IT CAPEX.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePolitical Factor\u003c\/th\u003e\n\u003cth\u003eKey 2024–25 Data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eExport controls\/tariffs\u003c\/td\u003e\n\u003ctd\u003eElectronics margin 6.8% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealthcare policy\/reimbursement\u003c\/td\u003e\n\u003ctd\u003eJapan fee cuts up to 1.5%; US\/EU spend growth 2.1% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiopharma subsidies\u003c\/td\u003e\n\u003ctd\u003e\u0026gt; $50bn (2024–25); Fujifilm biopharma ¥357.6bn FY2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eData localization\/compliance\u003c\/td\u003e\n\u003ctd\u003eGlobal healthcare cloud $65.4bn (2024); GDPR fines €2.3B (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect Fujifilm Holdings across six dimensions—Political, Economic, Social, Technological, Environmental, and Legal—combining data and trends to highlight strategic risks and opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, shareable PESTLE snapshot for Fujifilm that’s visually segmented by category, simplifying external risk assessment and market-position discussions for quick inclusion in presentations, strategy sessions, or client reports.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExchange Rate Fluctuations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs a Japanese multinational, Fujifilm faces material exposure to yen volatility versus the dollar and euro; FY2024 reported roughly 40% of revenues sourced outside Japan, magnifying FX impact when USD\/JPY moved from ~135 to ~150 in 2023–24. Currency swings affect export competitiveness and repatriated earnings—Fujifilm booked ¥12–15bn FX-related gains\/losses in recent years—so hedging programs and localized production in US\/EU are central to stabilizing margins and cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Inflationary Pressures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRising raw material, energy and logistics costs—polymer and chemical prices up ~18% YoY in 2024 and Japan wholesale energy up ~12%—squeezed Fujifilm’s margins across Materials and Imaging, contributing to a 2024 gross margin decline versus 2023. Management has implemented selective price hikes (photofinishing and inkjet media) while monitoring volume sensitivity in digital printing markets. Reduced purchasing power from tighter household real incomes and restrained hospital capital budgets risks lower unit demand for consumer photography products and some healthcare devices.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest Rate Environment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGlobal interest rate tightening since 2022 raised borrowing costs, pushing Fujifilm’s weighted average cost of capital higher and impacting financing for CDMO facility expansion—Japan’s 10-year JGB yield rose from ~0.05% in 2021 to ~0.9% in 2024, while US 10-year trebled to ~4.5%, increasing debt service on cross-border deals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEconomic Growth in Emerging Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eExpanding middle classes in India and Southeast Asia lift demand for Fujifilm’s healthcare diagnostics and consumer imaging; Asia accounted for about 42% of Fujifilm Holdings’ ¥2.5 trillion revenue in FY2024, with emerging markets growing faster than Japan and Americas.\u003c\/p\u003e\n\u003cp\u003eEconomic transitions in these regions offer diversification against stagnation in mature markets, where Fujifilm’s core imaging sales have flattened.\u003c\/p\u003e\n\u003cp\u003eLocalized pricing and distribution strategies have supported higher ASPs and a rising share of recurring diagnostic consumables, contributing to double-digit revenue growth in several Southeast Asian countries in 2023–2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAsia ~42% of FY2024 revenue (¥2.5T total)\u003c\/li\u003e\n\u003cli\u003eEmerging markets driving double-digit growth in 2023–2024\u003c\/li\u003e\n\u003cli\u003eLocalized pricing increases ASPs and recurring consumables sales\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInvestment Trends in Life Sciences\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eVenture capital and private equity investment in biotech reached about $47 billion globally in 2024, sustaining demand for Fujifilm’s CDMO and cell culture media services; a 20% pullback in early-stage funding during 2023–24 tightened smaller biotech R\u0026amp;D outsourcing. \u003c\/p\u003e\n\u003cp\u003eEconomic resilience for Fujifilm hinges on balancing contracts with cash-rich big pharma (top 10 pharma R\u0026amp;D spend ~ $140–160 billion annually) and flexible service models for startups facing funding volatility. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGlobal biotech VC\/PE ~ $47B (2024)\u003c\/li\u003e\n\u003cli\u003eEarly-stage funding down ~20% (2023–24)\u003c\/li\u003e\n\u003cli\u003eTop 10 pharma R\u0026amp;D ~ $140–160B\/yr\u003c\/li\u003e\n\u003cli\u003eRevenue mix diversification critical for CDMO demand\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFX, costs and rates squeeze margins as Asia growth and $47B biotech VC reshape outlook\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eYen volatility (USD\/JPY ~150 in 2024) and FX gains\/losses (~¥12–15bn) affect margins; raw material\/energy costs rose ~18%\/~12% in 2024 squeezing gross margin; higher rates (US 10y ~4.5%, JGB ~0.9%) raise WACC and CDMO financing costs; Asia ~42% of FY2024 ¥2.5T revenue with emerging markets double-digit growth; global biotech VC ~$47B (2024), early-stage funding down ~20%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUSD\/JPY\u003c\/td\u003e\n\u003ctd\u003e~150\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFX gains\/losses\u003c\/td\u003e\n\u003ctd\u003e¥12–15bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRaw materials ↑\u003c\/td\u003e\n\u003ctd\u003e~18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnergy ↑\u003c\/td\u003e\n\u003ctd\u003e~12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAsia revenue share\u003c\/td\u003e\n\u003ctd\u003e~42% of ¥2.5T\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiotech VC\u003c\/td\u003e\n\u003ctd\u003e$47B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eFujifilm Holdings PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Fujifilm Holdings PESTLE analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use for strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751242379641,"sku":"fujifilm-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/fujifilm-pestle-analysis.png?v=1772229245","url":"https:\/\/growthsharematrix.com\/products\/fujifilm-pestle-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}